• Giuseppe Lippi and Camilla Mattiuzzi.
• Section of Clinical Biochemistry, University of Verona, Verona, Italy.
• Arch Med Sci. 2020 Jan 1; 16 (4): 820-824.

IntroductionWe provide here an overview on current worldwide epidemiology of pancreatic malignancies, obtained from Global Health Data Exchange (GHDx) and World Health Organization (WHO) repositories.Material And MethodsElectronic searches for collecting information on pancreatic cancer epidemiology were performed in official repositories of GHDx and WHO, and retrieved data were then analyzed.ResultsOverall, 447 665 new cases of pancreatic cancer were recorded around the world in 2017 (58.6 per million), with global prevalence of 49.8 per million and 441 083 deaths (57.7 per million). Incidence, prevalence and mortality increased by 55%, 63% and 53% during the last 25 years. Pancreatic cancer accounts for 1.8% of all cancers, causing 3.9% of all cancer disability- adjusted life years (DALYs) and 4.6% of all cancer deaths. No sex differences can be observed for incidence, prevalence and mortality, whilst DALYs are marginally higher in men. Incidence, prevalence and mortality follow a similar age-related trend, with gradual escalation after 30 years of age, reaching the highest burden after 80 years of age. The DALYs peak between 55 and 74 years, and then decline. The epidemiologic burden is positively associated with socio-demographic status. The largest burden of pancreatic cancers is observed in the East and Asia Pacific region, whilst the lowest is found in the Middle East and North Africa. Pancreatic cancer deaths are expected to increase by ~1.97-fold by the year 2060.ConclusionsAlthough pancreatic cancer remains relatively infrequent, its clinical, societal and economic burden is noteworthy. Future projections suggest that its burden may double during the next 40 years.Copyright © 2020 Termedia & Banach.

4 keywords...

hide…